School of Medicine
Showing 1-10 of 83 Results
Demir Akin, D.V.M., Ph.D.
Deputy Director, Center for Cancer Nanotechnology Excellence, Rad/Molecular Imaging Program at Stanford
Current Role at StanfordDeputy Director, Center for Cancer Nanotechnology Excellence for Translational Diagnostics
Rad/Molecular Imaging Scientist, Rad/Molecular Imaging Program at Stanford
BioResearch Focus and interests: Molecular Imaging, PET, Immuno-Oncology, Graft versus Host Disease, CAR T cells
Dr. Israt Alam is a Research Scientist at the Radiology Department at Stanford University in Prof. Sanjiv Sam Gambhir's lab. Her research focuses on studying lymphocyte activation with the motivation of developing non-invasive imaging tools, to monitor immune dynamics in response to immunotherapy and for diagnosis of immune driven diseases. Her work has supported the clinical translation of several nuclear imaging agents for early disease diagnosis and prediction of treatment response for improved patient management.
-Post-Doctoral Scholar and Research Scientist, Department of Radiology, Stanford (2015-present)
-Visiting Researcher under supervision of Prof. Spencer Shorte, Plateforme d'imagerie dynamique, Pasteur Institute, Paris (2014)
-Science Education Intern and Consultant: United Nations Educational, Science and Cultural Organization (UNESCO), Paris (2012-2013)
Physical Science Research Professional 1, Rad/Molecular Imaging Program at Stanford
Current Role at StanfordMs. Azevedo focuses on the translation of radiotracers for imaging neurordegenerative diseases.
Vikram S Bajaj
Adjunct Professor, Rad/Molecular Imaging Program at Stanford
BioAdj. Professor, Stanford Radiology.
Managing Director, Foresite Capital Management
Co-Founder/CEO, Foresite Labs
Chief Scientific Officer, GRAIL
Chief Scientific Officer and Co-Founder, Verily (Google Life Sciences)
Instructor, Radiology - Rad/Molecular Imaging Program at Stanford
Current Research and Scholarly InterestsMy current research areas of interest include developing new strategies for: 1) novel radioligand and radiotracer development for various targets involved in brain cancer, 2) preclinical animal models of glioblastoma, and 3) clinical translation of useful radiopharmaceuticals for early-detection of disease and monitoring therapy.